Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Phase II Study for Treatment Peripheral T-cell Lymphoma, CHOP-14 Plus PEG-Filgrastim Followed by Alemtuzumab Consolidation

NCT01806337 is registered in ClinicalTrials.gov with University of Göttingen as lead sponsor.

NCT NCT01806337
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01806337 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Phase II Study for Treatment Peripheral T-cell Lymphoma, CHOP-14 Plus PEG-Filgrastim Followed by Alemtuzumab Consolidation
Lead sponsor
University of Göttingen
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2003
Completion date
February 28, 2011
Enrollment
41 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

peripheral t-cell lymphoma